BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as ...
Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...
Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer PURPOSE: To compare microsatellite instability (MSI) testing with immunohistochemical (IHC) ...
Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 ...
Abdul Rafeh Naqash, M.D., is an assistant professor of medicine in the University of Oklahoma College of Medicine and research member of the OU Health Stephenson Cancer Center. Not all cancer ...
IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting data at the 2023 American Association of Cancer Research (AACR) Annual Meeting ...
Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy. Most patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback